MariJo Logeman Gleeson, CPA, is an accomplished financial professional with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Chief Financial Officer at CeleCor Therapeutics since 2017, MariJo oversees financial operations for a clinical-stage company. With a consultancy role dating back to 2012, MariJo provides strategic financial guidance to life science organizations at various stages of development. Previous positions include Senior Director of Finance at AnaptysBio and VentiRx Pharmaceuticals, as well as financial consultancy for multiple firms, including Ciclofilin Pharmaceuticals and Solstice Biologics. MariJo holds a Master of Science in Health Policy and Management from Harvard T.H. Chan School of Public Health and a Bachelor of Business Administration from the University of Notre Dame.
CeleCor Therapeutics
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and laterdevelopment of heart failure.